Beta Drugs Limited Makes History: Unveiling the First NDDS Formulation of Megestrol Acetate Suspension in India

Beta Drugs Limited Makes History: Unveiling the First NDDS Formulation of Megestrol Acetate Suspension in India

Beta Drugs Limited achieves a significant milestone with the introduction of the first-ever NDDS (Novel Drug Delivery System) formulation of Megestrol Acetate Suspension 40mg/ml in India, branded as Caxfila-OS. This groundbreaking launch underscores the company’s dedication to advancing healthcare and addressing unmet needs in cancer treatment.

Megestrol Acetate Suspension, a liquid formulation of megestrol acetate, serves as a vital solution for managing anorexia, cachexia, and significant weight loss in cancer and AIDS patients. Designed as a synthetic progestin, it offers enhanced convenience and efficacy in addressing various women’s health challenges.

The innovative formulation represents a leap forward in providing an effective dosage form, optimizing therapeutic impact, and enhancing patient adherence compared to existing oral dosage forms of Megestrol Acetate.

This milestone launch coincides with Beta Drugs Limited’s recent establishment of a state-of-the-art oral suspension plant for cancer medicines. This facility, dedicated to manufacturing suspensions and dry syrups of existing cytotoxic drugs, underscores the company’s commitment to advancing cancer treatment options and elevating industry standards.

With world-class infrastructure adhering to the highest global regulatory standards and equipped with cutting-edge technology, Beta Drugs Limited aims to solidify its presence not only in the Indian market but also in regions worldwide.

As one of the few Indian oncology companies prioritizing research and development, Beta Drugs Limited’s relentless pursuit of innovation includes the development of more than 15 NDDS formulations by 2024. From Liposomes to Nanoparticles, Micro particulate systems, suspensions, and dry syrups, these formulations aim to enhance existing oncology treatments and reshape the landscape of cancer care.

As Beta Drugs Limited continues to push boundaries and set new standards, this monumental achievement promises to bring hope and improved healthcare to patients globally, marking a significant step forward in the fight against cancer.